Buy Vincristine 1 & 2 MG (Criston) - Mediaid pharmacy

Vincristine 1 & 2 MG (Criston)

Product Name : Vincristine
Generic Name : Criston
Formulation : Injection
Available Pack Size : 1’s
Available Strengths : 1 & 2 mg
Registrations : Bangladesh

Message Us on WhatsApp

Product Information

For Intravenous Use Only — Fatal If Given By Any Other Route

Intrathecal (spinal) administration of Vincristine is almost always fatal. This is one of the most serious and best-documented “never events” in oncology pharmacy. To prevent fatal mix-ups with medications that are given intrathecally (such as methotrexate or cytarabine), Vincristine should be diluted and dispensed in a flexible plastic minibag rather than a syringe wherever possible, must never be stored, transported, or handled alongside intrathecal medications, and any syringe containing Vincristine must carry a prominent overwrap label stating “Do not remove covering until moment of injection. For intravenous use only. Fatal if given by other routes.” Only individuals experienced in the administration of Vincristine should prepare or give this medication, with an independent second check of the drug, dose, and route before every administration.

Criston (Vincristine) 1mg & 2mg is a vinca alkaloid chemotherapy agent, given intravenously as part of multi-drug combination regimens, used in the treatment of acute lymphoblastic leukaemia, Hodgkin and non-Hodgkin lymphoma, and certain paediatric solid tumours such as rhabdomyosarcoma, neuroblastoma, and Wilms tumour. It works by blocking the formation of microtubules that cancer cells need to divide, halting cell replication. Manufactured for the Bangladesh market and globally supplied by Mediaid Pharmacy with worldwide shipping.

Note: this listing describes conventional Vincristine Sulfate Injection. It has different dosing from liposomal vincristine formulations, which are a distinct product with different maximum doses; always verify the exact drug name and formulation before preparing or administering any dose.

Basic Product Information of Criston (Vincristine) 1mg & 2mg

Brand Name	Criston (Vincristine) — please confirm brand/generic naming before publishing; “Vincristine” is the generic/INN name and “Criston” appears to be the brand, based on your naming pattern for previous products
Generic Name	Vincristine Sulfate INN
Drug Class	Vinca Alkaloid (Mitotic Inhibitor)
Available Strengths	1mg and 2mg (1mg/mL concentration, 2mL fill per vial)
Formulation	Sterile, Preservative-Free Injection, for Intravenous Use Only
Pack Size	1’s (single vial per pack), available in 1mg and 2mg vial sizes.
Primary Indication	Acute Lymphoblastic Leukaemia; Hodgkin and Non-Hodgkin Lymphoma; Selected Paediatric Solid Tumours
Regulatory Approvals	USFDA Approved (acute leukaemia; used within combination regimens for Hodgkin lymphoma, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumour). EMA Approved (equivalent indications).
Originator/Reference Brand	Originally marketed as Oncovin; now widely available as generic Vincristine Sulfate Injection from multiple manufacturers.
Manufacturer	[Manufacturer name to be confirmed], Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration	Registered in Bangladesh
Storage Conditions	Store refrigerated at 2°C to 8°C, protected from light, upright in the original carton until use. Do not freeze. This is a hazardous drug — follow applicable special handling and disposal procedures, and store and label separately from any intrathecal medications. Keep out of the reach of children.

How Criston (Vincristine) Works

Criston contains Vincristine Sulfate, an alkaloid originally derived from the periwinkle plant (Vinca rosea). Vincristine works by binding to tubulin, the protein building block of microtubules, and preventing microtubules from assembling correctly. Microtubules form the mitotic spindle that cells need to separate their chromosomes during division.

By disrupting this process, Vincristine arrests cancer cells in metaphase, the stage of cell division where chromosomes line up before separating, preventing the cell from completing division and ultimately leading to cell death. Because this mechanism targets actively dividing cells generally, Vincristine is typically combined with other chemotherapy agents that work through different mechanisms as part of an established multi-drug regimen, rather than used alone.

Criston is given intravenously only, typically as a bolus injection over about one minute or as a short infusion through a free-flowing IV line, by healthcare professionals experienced in its administration.

Indications for Criston (Vincristine)

Criston (Vincristine) is indicated for the following, generally as part of a multi-drug regimen:

Acute Lymphoblastic Leukaemia

For paediatric and adult patients with ALL, typically as part of induction or maintenance combination regimens.

Hodgkin and Non-Hodgkin Lymphoma

Used within established combination chemotherapy regimens for both Hodgkin and non-Hodgkin lymphoma.

Paediatric Solid Tumours

Used within combination regimens for rhabdomyosarcoma, neuroblastoma, and Wilms tumour, among other paediatric malignancies.

Benefits of Criston (Vincristine)

Cornerstone of Multiple Regimens

A core component of numerous well-established combination chemotherapy protocols across leukaemia, lymphoma, and paediatric solid tumours.

Distinct, Complementary Mechanism

Works by blocking cell division machinery, a mechanism distinct from and complementary to alkylating agents, antimetabolites, and anthracyclines used alongside it.

Long Clinical Track Record

Decades of use in paediatric and adult oncology have generated an extensive body of protocol-level experience.

Two Vial Sizes

Available as 1mg and 2mg vials, supporting precise, individualised dosing in line with strict body-surface-area calculations.

Relatively Modest Myelosuppression

Compared with many other chemotherapy agents, Vincristine causes comparatively less bone marrow suppression at standard doses, which can support its use in combination with more myelosuppressive drugs.

WHO-GMP and cGMP Certified

Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Criston meets consistent quality and safety requirements.

Administration of Criston (Vincristine)

Route: Intravenous only. Never given intrathecally, intramuscularly, or subcutaneously — see the critical safety notice at the top of this page.

Typical adult dose: 1.4mg/m² intravenously, once weekly, as part of the specific combination protocol prescribed. Many institutions apply a maximum single dose cap (commonly 2mg) regardless of the body-surface-area calculation, per local protocol.

Typical paediatric dose: 1.5mg/m² to 2mg/m² intravenously, once weekly; for children weighing 10kg or less, a starting dose of 0.05mg/kg once weekly is often used instead, per the treating protocol.

Who administers it: Must be prepared and given only by healthcare professionals experienced in Vincristine administration, in a hospital or oncology setting, following strict double-checking procedures for drug, dose, and route.

Injection site care: Vincristine is a vesicant. The IV line must be confirmed as free-flowing before and during injection. If extravasation (leakage into surrounding tissue) is suspected, the injection is stopped immediately and managed according to institutional extravasation protocol, which may include local hyaluronidase and moderate heat.

Hepatic impairment: A 50% dose reduction is recommended for patients with a direct serum bilirubin above 3mg/100mL.

Combination regimen timing: When used with other agents such as asparaginase, the sequence and spacing of doses within the regimen matters and should follow the specific institutional protocol.

Monitoring and Key Toxicities

Beyond the fatal-if-intrathecal risk described above, the most significant ongoing concern with Criston is dose-related neurotoxicity, including peripheral sensory and motor neuropathy (numbness, tingling, weakness), and effects on the autonomic nervous system, most notably constipation and, in severe cases, paralytic ileus — many protocols include a prophylactic bowel regimen for this reason. Extreme care is used in calculating every dose, since overdosage can be very serious or fatal.

Regular monitoring includes neurological assessment at each visit, bowel function, complete blood counts, and liver function. Rarely, Vincristine can cause syndrome of inappropriate antidiuretic hormone secretion (SIADH), leading to low blood sodium. Report any new numbness, tingling, weakness, jaw pain, severe constipation, abdominal pain, or injection site pain, redness, or swelling to the care team immediately.

Drug Interactions and Important Information

Vincristine is partly metabolised through CYP3A4; strong CYP3A4 inhibitors (such as certain antifungals, macrolide antibiotics, and protease inhibitors) can increase Vincristine exposure and neurotoxicity risk. Co-administration with other neurotoxic medications can compound nerve-related side effects. Vincristine-containing regimens may reduce blood levels of phenytoin and other anticonvulsants, so levels should be monitored in patients taking these medications concurrently.

When used together with L-asparaginase, as is common in ALL regimens, the sequence of administration affects toxicity and should follow the specific institutional protocol. Always ensure the full combination regimen and all concurrent medications are reviewed by the treating oncology team before each dose.

Side Effects and Precautions

Common Side Effects

Peripheral neuropathy (numbness, tingling)

Constipation

Hair loss (alopecia)

Jaw pain

Nausea and vomiting

Mild, dose-related myelosuppression

Serious Warnings and Precautions

Fatal if given intrathecally — see the notice at the top of this page.

Severe or permanent neurotoxicity with overdosage or cumulative dosing.

Tissue necrosis if extravasation occurs during injection.

Paralytic ileus, particularly with concurrent neurotoxic drugs or in young children.

Rare SIADH and hyponatraemia.

Embryo-fetal toxicity; can cause fetal harm.

Who Should Use Criston (Vincristine)?

Criston is intended for paediatric and adult patients with acute lymphoblastic leukaemia, Hodgkin or non-Hodgkin lymphoma, or certain paediatric solid tumours, as part of an oncologist-directed multi-drug regimen. It is administered exclusively in a hospital or specialist oncology setting by healthcare professionals with specific training and experience in Vincristine’s preparation, dosing, and route-of-administration safeguards. Baseline neurological status, bowel habits, and liver function should be assessed before starting treatment.

Manufacturer

Criston (Vincristine) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of oncology medications. We ensure Criston (Vincristine) is accessible to hospitals and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Criston (Vincristine) from Mediaid Pharmacy?

Criston provides hospitals and oncology centres with a well-established vinca alkaloid chemotherapy option, backed by decades of protocol-level clinical use across paediatric and adult oncology. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Criston gives cancer centres worldwide access to this foundational medication at an accessible price. Given the exceptional route-of-administration risk specific to this medicine, Mediaid Pharmacy strongly encourages every receiving pharmacy and clinical team to have robust safeguards in place — including minibag dilution, separate storage from intrathecal medications, and independent double-checks — before Criston is ever administered.

Frequently Asked Questions About Criston (Vincristine)

What is Criston (Vincristine) used for?

Criston (Vincristine) is a vinca alkaloid chemotherapy agent used as part of combination regimens to treat acute lymphoblastic leukaemia, Hodgkin and non-Hodgkin lymphoma, and certain paediatric solid tumours such as rhabdomyosarcoma, neuroblastoma, and Wilms tumour. It works by blocking the machinery cancer cells need to divide.

Why is intrathecal administration of Vincristine so dangerous?

Vincristine given into the spinal fluid (intrathecally) is almost always fatal. This has happened in real hospitals worldwide, most often when Vincristine was confused with a different chemotherapy drug that is genuinely meant to be given intrathecally, such as methotrexate. For this reason, Vincristine is for intravenous use only, should be dispensed in a minibag rather than a syringe wherever possible, must be clearly labelled and stored separately from intrathecal medications, and should only be handled by staff following strict double-check procedures.

How is Criston (Vincristine) dosed?

The typical adult dose is 1.4mg/m² intravenously once weekly, and the typical paediatric dose is 1.5-2mg/m² once weekly, both as part of a specific combination protocol. Many institutions cap the single dose at 2mg regardless of the calculated amount. Doses are reduced by 50% in patients with significant liver impairment. The exact dose and schedule always follow the treating oncology protocol.

What strengths and pack size is Criston available in?

Criston is supplied as single-use vials in two sizes, 1mg and 2mg (1mg/mL concentration), packed as 1’s (one vial per pack). The hospital pharmacy selects the appropriate vial size and volume to prepare the exact dose calculated for each patient.

What are the side effects of Criston (Vincristine)?

Common side effects include numbness or tingling, constipation, hair loss, jaw pain, and nausea. Serious risks include severe nerve damage with excessive dosing, tissue damage if the drug leaks outside the vein during injection, and severe constipation or bowel blockage. Regular neurological and bowel monitoring is required throughout treatment. Always consult the treating oncologist for a complete assessment of individual risks and benefits.

Can hospitals order Criston (Vincristine) with worldwide shipping?

Yes. Mediaid Pharmacy supplies Criston (Vincristine) 1mg and 2mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.

Order Criston (Vincristine) 1mg & 2mg with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp